Ferroptosis-IN-8
Based on 1 Customer Validation
Ferroptosis-IN-8 is a potent ferroptosis inhibitor with an EC50 of 40.49 nM. Ferroptosis-IN-8 effectively reduces lipid ROS levels in cells. Ferroptosis-IN-8 act as an antioxidant by capturing lipid radicals, leading to a reduction in the accumulation of harmful lipid peroxides and, ultimately, inhibiting ferroptosis.
For research use only. We do not sell to patients.
- Purity : 98.24%
- CAS No.: 3056016-82-8
- Formula: C15H15N3O3
- Molecular Weight:285.30
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
IC50: 40.49 nM (Ferroptosis)
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-1080 | EC50 |
40.49 nM
Compound: B4
|
Inhibition of RSL3-induced ferroptosis in human HT-1080 cells assessed as cell viability incubated for 24 hrs by CCK8 assay
Inhibition of RSL3-induced ferroptosis in human HT-1080 cells assessed as cell viability incubated for 24 hrs by CCK8 assay
|
[PMID: 38822802] |
In Vitro
Ferroptosis-IN-8 (Compound B4) (200 nM) effectively rescues HKC, HK-2, Khos, SW480, and HTR-8/SVneo cells from ferroptosis induced by RSL3 or FIN56[1]. Ferroptosis-IN-8 (Compound B4) (200 nM) againstes ferroptosis predominantly relies on their intrinsic antioxidative capacity, rather than classical signaling pathways including lipid oxidation metabolism[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HKC, HK-2, HT-1080, Khos, SW480, and HTR-8/SVneo cells treatment with RSL3 or FIN56
-
Concentration:200 nM
-
Incubation Time:24 h
-
Result:Effectively rescued HKC, HK-2, HT-1080, Khos, SW480, and HTR-8/SVneo cells from ferroptosis induced by RSL3 or FIN56.
-
Cell Line:HT-1080 cell
-
Concentration:200 nM
-
Incubation Time:
-
Result:Didn't significantly affect the protein levels of key factors related to lipid metabolism (ACSL4, ALOX15, and COX2), glutathione metabolism pathways (GPX4, SLC7A11), and iron metabolism (DMT1, TFRC, and FTH1)
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:acetaminophen-induced acute liver injury mice model[1].
-
Dosage:10 mg/kg
-
Administration:intraperitoneal injection (i.p.)
-
Result:Attenuated the increased plasma ALT and AST levels induced by acetaminophen, effectively reduced the injury response induced by acetaminophen[1].
-
Animal Model:kidney ischemia−reperfusion injury mice model[1].
-
Dosage:10 mg/kg, twice, 1 h before ischemia onset.
-
Administration:intraperitoneal injection (i.p.)
-
Result:Reduced the levels of creatinine and BUN and alleviated the increase in KIM-1 levels in the I/R model[1].
-
Animal Model:
-
Dosage:
-
Administration:
-
Result:
-
Animal Model:
-
Dosage:
-
Administration:
-
Result:
Chemical Information
-
CAS No. 3056016-82-8
-
Appearance Solid
-
Molecular Weight 285.30
-
Formula C15H15N3O3
-
Color Yellow to orange
-
SMILES
NC1=C(C=CC=C1O)C(N/N=C/C2=CC=C(C=C2)OC)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (175.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5051 mL | 17.5254 mL | 35.0508 mL | 87.6271 mL |
| 5 mM | 0.7010 mL | 3.5051 mL | 7.0102 mL | 17.5254 mL | |
| 10 mM | 0.3505 mL | 1.7525 mL | 3.5051 mL | 8.7627 mL | |
| 15 mM | 0.2337 mL | 1.1684 mL | 2.3367 mL | 5.8418 mL | |
| 20 mM | 0.1753 mL | 0.8763 mL | 1.7525 mL | 4.3814 mL | |
| 25 mM | 0.1402 mL | 0.7010 mL | 1.4020 mL | 3.5051 mL | |
| 30 mM | 0.1168 mL | 0.5842 mL | 1.1684 mL | 2.9209 mL | |
| 40 mM | 0.0876 mL | 0.4381 mL | 0.8763 mL | 2.1907 mL | |
| 50 mM | 0.0701 mL | 0.3505 mL | 0.7010 mL | 1.7525 mL | |
| 60 mM | 0.0584 mL | 0.2921 mL | 0.5842 mL | 1.4605 mL | |
| 80 mM | 0.0438 mL | 0.2191 mL | 0.4381 mL | 1.0953 mL | |
| 100 mM | 0.0351 mL | 0.1753 mL | 0.3505 mL | 0.8763 mL |